Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. reports commercial-stage oncology developments centered on LOQTORZI® (toripalimab-tpzi), an approved next-generation PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma. Company updates also cover its antibody immunotherapy pipeline, including tagmokitug, an anti-CCR8 cytolytic antibody, and casdozokitug, an IL-27 antagonistic antibody, across solid-tumor programs such as liver, prostate, head and neck, colorectal, gastric and esophageal cancers.
Recurring news includes financial results, LOQTORZI revenue commentary, clinical-development updates, strategic partnerships, investor-conference presentations, public common-stock offerings, debt reduction and other capital-structure actions tied to the company's transition from biosimilars to innovative oncology.
Coherus Oncology (NASDAQ: CHRS) will participate in three investor conferences in New York: the Baird 2026 Global Healthcare Conference on September 15, 2026, at 7:55 a.m. EDT; the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 11:30 a.m. EDT; and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, at 12:20 p.m. EDT.
According to Coherus, live webcasts and 30‑day replays will be available via the Investor Events section of its website, and investors can request one‑on‑one meetings through their bank representatives.
Coherus Oncology (NASDAQ: CHRS) declared a special dividend of non-transferable contingent value rights (“CVRs”) to stockholders of record as of 5:00 p.m. ET on September 30, 2026, with distribution on October 7, 2026. Each CVR entitles holders to a pro rata share of any net cash proceeds Coherus actually receives from selling or otherwise monetizing its remaining Legacy BioSim Assets, including patents, intellectual property, a royalty stream, cell lines and related materials. The company plans to immediately launch a sale process for these assets and has retained an investment bank as advisor. The CVRs will not trade, bear interest, or confer equity or voting rights, and will expire on October 7, 2028. If no net proceeds are realized before expiration, the CVRs will lapse without payment. According to Coherus, this transaction completes its shift from biosimilars to a focused immuno-oncology business centered on LOQTORZI and its clinical pipeline.
Coherus Oncology (Nasdaq: CHRS) reported second quarter 2026 net revenue from continuing operations of $14.3 million, up from $10.3 million a year earlier, driven primarily by LOQTORZI. LOQTORZI net revenue reached $13.6 million, a 37% increase versus Q2 2025 and 15% above Q1 2026.
Cost of goods sold was $4.2 million, while R&D and SG&A expenses fell to $21.4 million and $21.0 million, respectively, reflecting lower headcount and the 2025 biosimilar exit. Net loss from continuing operations narrowed to $33.3 million (−$0.22 per diluted share) from $44.9 million (−$0.39) in Q2 2025; non-GAAP net loss was $30.1 million (−$0.19) versus $39.0 million (−$0.34). Cash, cash equivalents and marketable securities totaled $105.3 million at June 30, 2026, including TSA-related balances.
Clinically, Coherus advanced its pipeline: multiple Phase 1b/2a studies of tagmokitug in solid tumors and a randomized Phase 2 trial of casdozokitug in first-line unresectable hepatocellular carcinoma are ongoing, with initial data readouts and broader public disclosure expected in the second half of 2026.
Coherus Oncology (Nasdaq: CHRS) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, followed by a management conference call and webcast starting at 5:00 p.m. Eastern Daylight Time. Investors can pre-register online to receive dial-in details and a personal PIN, or access the live and archived webcast via the Coherus investors website.
According to Coherus Oncology, the company uses its investors website for disclosure of material information under Regulation FD. The release also highlights LOQTORZI, an approved PD-1 inhibitor, and mid-stage pipeline candidates tagmokitug and casdozokitug in various solid tumor indications.
Coherus Oncology (Nasdaq: CHRS) and Zumutor Biologics announced a clinical collaboration and supply agreement to evaluate ZM008, an anti-LLT1 monoclonal antibody, in combination with LOQTORZI (toripalimab-tpzi) in a Phase 1 trial (NCT06451497).
The US study has dosed its first patient and will enroll up to 45 patients with multiple solid tumors, assessing safety, tolerability and recommended dose. Coherus supplies LOQTORZI; Zumutor sponsors the trial, and both retain commercial rights to their own compounds.
Coherus Oncology (Nasdaq: CHRS) reported Q1 2026 net revenue from continuing operations of $12.3 million, with LOQTORZI net revenue of $11.8 million, up 61% year over year and down 5% sequentially. Net loss narrowed to $36.9 million from $47.4 million.
Cash, cash equivalents and marketable securities totaled $167.0 million at March 31, 2026. The company raised $53.6 million net via a public offering of 32.89 million shares. Key pipeline updates include full enrollment of the randomized Phase 2 casdozokitug uHCC trial and multiple ongoing Phase 1b tagmokitug combination studies with data readouts expected in 2026.
Coherus Oncology (Nasdaq: CHRS) will release first quarter 2026 financial results after market close on Monday, May 11, 2026.
The company will host a management conference call and webcast starting at 5:00 p.m. Eastern Time on May 11, 2026. A replay and press release will be available at https://investors.coherus.com.
Coherus Oncology (NASDAQ: CHRS) reported full-year and Q4 2025 results, highlighting commercial growth for LOQTORZI, major debt reduction, cash position and pipeline progress. LOQTORZI revenue more than doubled to $40.8M in 2025. Secured and convertible debt was reduced ~90% to $38.8M. Cash and marketable securities totaled $172.1M at year-end. The company reported a 2025 net loss of $183.1M and ongoing R&D investment in tagmokitug and casdozokitug with multiple clinical readouts expected in 2026.
Notable clinical data include a 6-year OS median of 64.8 months vs 33.7 months for chemotherapy in JUPITER-02 (HR 0.62), and a prior Phase 2 casdozokitug CR rate of 17%.
Coherus Oncology (Nasdaq: CHRS) will release its full year and fourth quarter 2025 financial results after market close on Monday, March 9, 2026. A management conference call and webcast will begin at 4:30 p.m. ET the same day, with a replay posted on the company investor website.
Investors can pre-register for dial-in details and PIN, and the press release and related materials will be available on the Coherus investor site before the call.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at two investor conferences in March 2026 with webcasts and replays available on the company investor events calendar.
Presentations: TD Cowen Healthcare Conference on March 4, 2026 at 11:50 AM ET and Citizens Life Sciences Conference on March 10, 2026 at 2:50 PM ET. Replays will be posted for approximately 90 days.